The absence of a control group precludes definitive conclusions on causality between GLP-1 receptor agonist therapy and observed outcomes, and residual confounding cannot be excluded In conclusion, arGLP-1 represent a valuable addition to the therapeutic arsenal for managing IWL or WR after BS
In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo
Radiation can reduce the risk of local recurrence, although its impact on overall survival remains limited
This is also important if you are comparing Wegovy, Ozempic, or other semaglutide options, asking about prescription savings, or planning long-term weight loss treatment
CrossRef The dual burden of obesity: decoding metabolism and female reproductive endocrinology Yan Chen, Rongyu Wang, Nannan Zhang, Liangzhi Xu Frontiers in Physiology.2025;[Epub] CrossRef High-Density Lipoprotein Dysfunction and Atherosclerotic Cardiovascular Disease: From Quantity to Quality Amogh Jyothi Arun, Shigeru Kaneki, Madiha Baig, William H